Risk of male breast cancer after Hodgkin lymphoma

BETER Consortium; Simone de Vries; Inge M. Krul; Michael Schaapveld; Cecile P.M. Janus; Saskia E. Rademakers; J. M. Roesink; M. R. Nijziel; M. Y. Bilgin; F. E. van Leeuwen; A. Nijdam; Berthe M.P. Aleman; J. P. de Boer; Cecile P.M. Janus; P. G.N.J. Mutsaers; C. So-Osman; J. M. Zijlstra; O. W.M. Meijer; S. E. Rademakers; A. D.G. Krol; M. J. Kersten; S. H. Tonino; M. Jalink; L. A. Daniëls; D. J. van Spronsen; R. W.M. van der Maazen; J. Loonen; J. M. Roesink; R. Oostvogels; R. de Weijer; D. Buter; A. de Boer; K. M. Aarsman; C. W. Oudbier; M. van den Berg; K. Verschueren; M. Schippers; K. Muller; C. Siemes; J. M. van der Spek; A. Jonkman; E. de Jongh; S. Sprangers; J. Paulissen; E. F.M. Posthuma; R. E. Brouwer; S. Soechit; M. Y. Bilgin; S. Kuipers; L. te Boome; S. Gommers

doi:10.1182/blood.2023020940

Risk of male breast cancer after Hodgkin lymphoma

BETER Consortium, Simone de Vries, Inge M. Krul, Michael Schaapveld, Cecile P.M. Janus, Saskia E. Rademakers, J. M. Roesink, M. R. Nijziel, M. Y. Bilgin, F. E. van Leeuwen^*, A. Nijdam, Berthe M.P. Aleman, J. P. de Boer, Cecile P.M. Janus, P. G.N.J. Mutsaers, C. So-Osman, J. M. Zijlstra, O. W.M. Meijer, S. E. Rademakers, A. D.G. KrolM. J. Kersten, S. H. Tonino, M. Jalink, L. A. Daniëls, D. J. van Spronsen, R. W.M. van der Maazen, J. Loonen, J. M. Roesink, R. Oostvogels, R. de Weijer, D. Buter, A. de Boer, K. M. Aarsman, C. W. Oudbier, M. van den Berg, K. Verschueren, M. Schippers, K. Muller, C. Siemes, J. M. van der Spek, A. Jonkman, E. de Jongh, S. Sprangers, J. Paulissen, E. F.M. Posthuma, R. E. Brouwer, S. Soechit, M. Y. Bilgin, S. Kuipers, L. te Boome, S. Gommers

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

3 Citations (Web of Science)

12 Downloads (Pure)

Abstract

Female survivors of Hodgkin lymphoma (HL) treated with chest radiotherapy have a strongly increased risk of breast cancer (BC), but the treatment-specific BC risk in male survivors of HL has not been evaluated. We assessed BC risk in a cohort of 3077 male survivors of 5-year HL treated at age ≤51 years in 20 Dutch hospitals between 1965 and 2013. We estimated standardized incidence ratios (SIRs), absolute excess risks per 10 000 person-years, and cumulative BC incidences. After a 20-year median follow-up, we observed 8 cases of male with BC. Male survivors of HL experienced a 23-fold (95% confidence interval [CI], 10.1-46.0) increased BC risk compared with the general population, representing 1.6 (95% CI, 0.7-3.3) excess BC incidences per 10 000 person-years. The 20- and 40-year cumulative BC incidences after HL treatment were 0.1% (95% CI, 0.02-0.3) and 0.7% (95% CI, 0.3-1.4), respectively. Treatment with chest radiotherapy without alkylating chemotherapy yielded a strongly increased SIR (20.7; 95% CI, 2.5-74.8), which was not significantly different for chest radiotherapy and alkylating chemotherapy (41.1; 95% CI, 13.4-96.0). Males treated with chest radiotherapy and anthracyclines had an SIR of 48.1 (95% CI, 13.1-123.1). Two patients died from BC (median follow-up, 4.7 years). To ensure early diagnosis and treatment, clinicians should be alert to BC symptoms in male survivors of HL.

Original language	English
Pages (from-to)	806-811
Number of pages	6
Journal	Blood
Volume	142
Issue number	9
DOIs	https://doi.org/10.1182/blood.2023020940
Publication status	Published - 31 Aug 2023

Bibliographical note

Funding Information:
This work was supported by the Dutch Cancer Society (NKI 2010-4720 ) (F.E.v.L.).

Funding Information:
The authors thank Rosemarie Wijnands for the data support at the Netherlands Cancer Institute. This work was supported by the Dutch Cancer Society (NKI 2010-4720) (F.E.v.L.). Contribution: S.d.V. I.M.K. B.M.P.A. and F.E.v.L. designed the study; C.P.M.J. S.E.R. J.M.R. M.R.N. Y.M.B. B.M.P.A. and the BETER consortium provided study patients; S.d.V. M.S. and F.E.v.L. collected and assembled data; S.d.V. I.M.K. M.S. B.M.P.A. and F.E.v.L. analyzed and interpreted data; S.d.V. I.M.K. and F.E.v.L. contributed to manuscript writing; and all authors approved the final manuscript.

Publisher Copyright:
© 2023 The American Society of Hematology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1182/blood.2023020940

Risk of male breast cancer after Hodgkin lymphomaAccepted author manuscript, 257 KBLicence: CC BY-NC-ND

Cite this

BETER Consortium, de Vries, S., Krul, I. M., Schaapveld, M., Janus, C. P. M., Rademakers, S. E., Roesink, J. M., Nijziel, M. R., Bilgin, M. Y., van Leeuwen, F. E., Nijdam, A., Aleman, B. M. P., de Boer, J. P., Janus, C. P. M., Mutsaers, P. G. N. J., So-Osman, C., Zijlstra, J. M., Meijer, O. W. M., Rademakers, S. E., ... Gommers, S. (2023). Risk of male breast cancer after Hodgkin lymphoma. Blood, 142(9), 806-811. https://doi.org/10.1182/blood.2023020940

@article{75e68bb3a17c4cad9f8a32406aaf73e8,

title = "Risk of male breast cancer after Hodgkin lymphoma",

abstract = "Female survivors of Hodgkin lymphoma (HL) treated with chest radiotherapy have a strongly increased risk of breast cancer (BC), but the treatment-specific BC risk in male survivors of HL has not been evaluated. We assessed BC risk in a cohort of 3077 male survivors of 5-year HL treated at age ≤51 years in 20 Dutch hospitals between 1965 and 2013. We estimated standardized incidence ratios (SIRs), absolute excess risks per 10 000 person-years, and cumulative BC incidences. After a 20-year median follow-up, we observed 8 cases of male with BC. Male survivors of HL experienced a 23-fold (95% confidence interval [CI], 10.1-46.0) increased BC risk compared with the general population, representing 1.6 (95% CI, 0.7-3.3) excess BC incidences per 10 000 person-years. The 20- and 40-year cumulative BC incidences after HL treatment were 0.1% (95% CI, 0.02-0.3) and 0.7% (95% CI, 0.3-1.4), respectively. Treatment with chest radiotherapy without alkylating chemotherapy yielded a strongly increased SIR (20.7; 95% CI, 2.5-74.8), which was not significantly different for chest radiotherapy and alkylating chemotherapy (41.1; 95% CI, 13.4-96.0). Males treated with chest radiotherapy and anthracyclines had an SIR of 48.1 (95% CI, 13.1-123.1). Two patients died from BC (median follow-up, 4.7 years). To ensure early diagnosis and treatment, clinicians should be alert to BC symptoms in male survivors of HL.",

author = "{BETER Consortium} and {de Vries}, Simone and Krul, {Inge M.} and Michael Schaapveld and Janus, {Cecile P.M.} and Rademakers, {Saskia E.} and Roesink, {J. M.} and Nijziel, {M. R.} and Bilgin, {M. Y.} and {van Leeuwen}, {F. E.} and A. Nijdam and Aleman, {Berthe M.P.} and {de Boer}, {J. P.} and Janus, {Cecile P.M.} and Mutsaers, {P. G.N.J.} and C. So-Osman and Zijlstra, {J. M.} and Meijer, {O. W.M.} and Rademakers, {S. E.} and Krol, {A. D.G.} and Kersten, {M. J.} and Tonino, {S. H.} and M. Jalink and Dani{\"e}ls, {L. A.} and {van Spronsen}, {D. J.} and {van der Maazen}, {R. W.M.} and J. Loonen and Roesink, {J. M.} and R. Oostvogels and {de Weijer}, R. and D. Buter and {de Boer}, A. and Aarsman, {K. M.} and Oudbier, {C. W.} and {van den Berg}, M. and K. Verschueren and M. Schippers and K. Muller and C. Siemes and {van der Spek}, {J. M.} and A. Jonkman and {de Jongh}, E. and S. Sprangers and J. Paulissen and Posthuma, {E. F.M.} and Brouwer, {R. E.} and S. Soechit and Bilgin, {M. Y.} and S. Kuipers and {te Boome}, L. and S. Gommers",

note = "Funding Information: This work was supported by the Dutch Cancer Society (NKI 2010-4720 ) (F.E.v.L.). Funding Information: The authors thank Rosemarie Wijnands for the data support at the Netherlands Cancer Institute. This work was supported by the Dutch Cancer Society (NKI 2010-4720) (F.E.v.L.). Contribution: S.d.V. I.M.K. B.M.P.A. and F.E.v.L. designed the study; C.P.M.J. S.E.R. J.M.R. M.R.N. Y.M.B. B.M.P.A. and the BETER consortium provided study patients; S.d.V. M.S. and F.E.v.L. collected and assembled data; S.d.V. I.M.K. M.S. B.M.P.A. and F.E.v.L. analyzed and interpreted data; S.d.V. I.M.K. and F.E.v.L. contributed to manuscript writing; and all authors approved the final manuscript. Publisher Copyright: {\textcopyright} 2023 The American Society of Hematology",

year = "2023",

month = aug,

day = "31",

doi = "10.1182/blood.2023020940",

language = "English",

volume = "142",

pages = "806--811",

journal = "Blood",

issn = "0006-4971",

publisher = "Elsevier",

number = "9",

}

BETER Consortium, de Vries, S, Krul, IM, Schaapveld, M, Janus, CPM, Rademakers, SE, Roesink, JM, Nijziel, MR, Bilgin, MY, van Leeuwen, FE, Nijdam, A, Aleman, BMP, de Boer, JP, Janus, CPM , Mutsaers, PGNJ , So-Osman, C, Zijlstra, JM, Meijer, OWM, Rademakers, SE, Krol, ADG, Kersten, MJ, Tonino, SH, Jalink, M, Daniëls, LA, van Spronsen, DJ, van der Maazen, RWM, Loonen, J, Roesink, JM, Oostvogels, R, de Weijer, R, Buter, D, de Boer, A, Aarsman, KM, Oudbier, CW, van den Berg, M, Verschueren, K, Schippers, M, Muller, K, Siemes, C, van der Spek, JM, Jonkman, A, de Jongh, E, Sprangers, S, Paulissen, J, Posthuma, EFM, Brouwer, RE, Soechit, S, Bilgin, MY, Kuipers, S, te Boome, L & Gommers, S 2023, 'Risk of male breast cancer after Hodgkin lymphoma', Blood, vol. 142, no. 9, pp. 806-811. https://doi.org/10.1182/blood.2023020940

TY - JOUR

T1 - Risk of male breast cancer after Hodgkin lymphoma

AU - BETER Consortium

AU - de Vries, Simone

AU - Krul, Inge M.

AU - Schaapveld, Michael

AU - Janus, Cecile P.M.

AU - Rademakers, Saskia E.

AU - Roesink, J. M.

AU - Nijziel, M. R.

AU - Bilgin, M. Y.

AU - van Leeuwen, F. E.

AU - Nijdam, A.

AU - Aleman, Berthe M.P.

AU - de Boer, J. P.

AU - Janus, Cecile P.M.

AU - Mutsaers, P. G.N.J.

AU - So-Osman, C.

AU - Zijlstra, J. M.

AU - Meijer, O. W.M.

AU - Rademakers, S. E.

AU - Krol, A. D.G.

AU - Kersten, M. J.

AU - Tonino, S. H.

AU - Jalink, M.

AU - Daniëls, L. A.

AU - van Spronsen, D. J.

AU - van der Maazen, R. W.M.

AU - Loonen, J.

AU - Roesink, J. M.

AU - Oostvogels, R.

AU - de Weijer, R.

AU - Buter, D.

AU - de Boer, A.

AU - Aarsman, K. M.

AU - Oudbier, C. W.

AU - van den Berg, M.

AU - Verschueren, K.

AU - Schippers, M.

AU - Muller, K.

AU - Siemes, C.

AU - van der Spek, J. M.

AU - Jonkman, A.

AU - de Jongh, E.

AU - Sprangers, S.

AU - Paulissen, J.

AU - Posthuma, E. F.M.

AU - Brouwer, R. E.

AU - Soechit, S.

AU - Bilgin, M. Y.

AU - Kuipers, S.

AU - te Boome, L.

AU - Gommers, S.

N1 - Funding Information: This work was supported by the Dutch Cancer Society (NKI 2010-4720 ) (F.E.v.L.). Funding Information: The authors thank Rosemarie Wijnands for the data support at the Netherlands Cancer Institute. This work was supported by the Dutch Cancer Society (NKI 2010-4720) (F.E.v.L.). Contribution: S.d.V. I.M.K. B.M.P.A. and F.E.v.L. designed the study; C.P.M.J. S.E.R. J.M.R. M.R.N. Y.M.B. B.M.P.A. and the BETER consortium provided study patients; S.d.V. M.S. and F.E.v.L. collected and assembled data; S.d.V. I.M.K. M.S. B.M.P.A. and F.E.v.L. analyzed and interpreted data; S.d.V. I.M.K. and F.E.v.L. contributed to manuscript writing; and all authors approved the final manuscript. Publisher Copyright: © 2023 The American Society of Hematology

PY - 2023/8/31

Y1 - 2023/8/31

N2 - Female survivors of Hodgkin lymphoma (HL) treated with chest radiotherapy have a strongly increased risk of breast cancer (BC), but the treatment-specific BC risk in male survivors of HL has not been evaluated. We assessed BC risk in a cohort of 3077 male survivors of 5-year HL treated at age ≤51 years in 20 Dutch hospitals between 1965 and 2013. We estimated standardized incidence ratios (SIRs), absolute excess risks per 10 000 person-years, and cumulative BC incidences. After a 20-year median follow-up, we observed 8 cases of male with BC. Male survivors of HL experienced a 23-fold (95% confidence interval [CI], 10.1-46.0) increased BC risk compared with the general population, representing 1.6 (95% CI, 0.7-3.3) excess BC incidences per 10 000 person-years. The 20- and 40-year cumulative BC incidences after HL treatment were 0.1% (95% CI, 0.02-0.3) and 0.7% (95% CI, 0.3-1.4), respectively. Treatment with chest radiotherapy without alkylating chemotherapy yielded a strongly increased SIR (20.7; 95% CI, 2.5-74.8), which was not significantly different for chest radiotherapy and alkylating chemotherapy (41.1; 95% CI, 13.4-96.0). Males treated with chest radiotherapy and anthracyclines had an SIR of 48.1 (95% CI, 13.1-123.1). Two patients died from BC (median follow-up, 4.7 years). To ensure early diagnosis and treatment, clinicians should be alert to BC symptoms in male survivors of HL.

AB - Female survivors of Hodgkin lymphoma (HL) treated with chest radiotherapy have a strongly increased risk of breast cancer (BC), but the treatment-specific BC risk in male survivors of HL has not been evaluated. We assessed BC risk in a cohort of 3077 male survivors of 5-year HL treated at age ≤51 years in 20 Dutch hospitals between 1965 and 2013. We estimated standardized incidence ratios (SIRs), absolute excess risks per 10 000 person-years, and cumulative BC incidences. After a 20-year median follow-up, we observed 8 cases of male with BC. Male survivors of HL experienced a 23-fold (95% confidence interval [CI], 10.1-46.0) increased BC risk compared with the general population, representing 1.6 (95% CI, 0.7-3.3) excess BC incidences per 10 000 person-years. The 20- and 40-year cumulative BC incidences after HL treatment were 0.1% (95% CI, 0.02-0.3) and 0.7% (95% CI, 0.3-1.4), respectively. Treatment with chest radiotherapy without alkylating chemotherapy yielded a strongly increased SIR (20.7; 95% CI, 2.5-74.8), which was not significantly different for chest radiotherapy and alkylating chemotherapy (41.1; 95% CI, 13.4-96.0). Males treated with chest radiotherapy and anthracyclines had an SIR of 48.1 (95% CI, 13.1-123.1). Two patients died from BC (median follow-up, 4.7 years). To ensure early diagnosis and treatment, clinicians should be alert to BC symptoms in male survivors of HL.

UR - http://www.scopus.com/inward/record.url?scp=85166190304&partnerID=8YFLogxK

U2 - 10.1182/blood.2023020940

DO - 10.1182/blood.2023020940

M3 - Article

C2 - 37390297

AN - SCOPUS:85166190304

SN - 0006-4971

VL - 142

SP - 806

EP - 811

JO - Blood

JF - Blood

IS - 9

ER -

Risk of male breast cancer after Hodgkin lymphoma

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this